Patient characteristics
| Variable . | Refractory to eltrombopag (n = 35) . | Responders to eltrombopag (n = 35) . | Statistical significance (P) . |
|---|---|---|---|
| No. of DNA variants present in the patient, median [Q1-Q3] | 4 [3-5] | 2 [1-2] | <.001 |
| Age at diagnosis, y, median [Q1-Q3] | 48 [38-69] | 55 [43-67] | .447 |
| Age at diagnosis ≥ 65 y, n (%) | 11 (31.4) | 10 (28.6) | .794 |
| Male/female, n | 18/17 | 11/24 | .089 |
| CCI > 1, n (%) | 2 (5.7) | 5 (14.3) | .232 |
| Months with ITP, median [Q1-Q3] | 14 [8-114] | 12 [5-55] | .039 |
| Platelet count at diagnosis (×109/L), median [Q1-Q3] | 7 [4-16] | 16 [6-30] | .202 |
| Asymptomatic at diagnosis, n (%) | 19 (59.4) | 26 (74.3) | .194 |
| Bleeding at diagnosis, n (%) | 24 (75.0) | 21 (60.0) | .192 |
| Type of primary ITP, n (%) | 35 (100) | 35 (100) | |
| Newly diagnosed | 5 (14.3) | 8 (22.9) | .356 |
| Persistent | 6 (17.1) | 8 (22.9) | .550 |
| Chronic | 24 (68.6) | 19 (54.3) | .220 |
| Eltrombopag treatment duration (mo), median [Q1;Q3] | 3 [1;9] | 44 [27;75] | < .001 |
| Past ITP treatments, median [Q1-Q3] | 2 [2-4] | 1 [1-3] | .005 |
| Romiplostim, n (%) | 14 (40.0) | 4 (11.4) | .006 |
| IV immunoglobulins, n (%) | 16 (45.7) | 8 (22.9) | .044 |
| Rituximab, n (%) | 12 (34.3) | 2 (5.7) | .003 |
| Splenectomy, n (%) | 14 (40.0) | 2 (5.7) | .001 |
| Vincristine, n (%) | 1 (2.9) | 2 (5.7) | .555 |
| Three or more previous treatment lines, n (%) | 17 (48.6) | 9 (25.7) | .048 |
| Platelet count at eltrombopag treatment initiation (×109/L), median [Q1-Q3] | 8 [5-30] | 25 [10-43] | .005 |
| Bleeding at eltrombopag treatment initiation, n (%) | 19 (54.3) | 7 (20.0) | .003 |
| Platelet count at last visit under eltrombopag treatment (×109/L), median [Q1-Q3] | 15 [8-26] | 125 [105-174] | <.001 |
| Platelet count at last visit follow-up under any ITP drug (×109/L), median [Q1-Q3] | 65 [22-115] | 126 [110-182] | .003 |
| Platelet count at last visit follow-up (×109/L), median [Q1-Q3] | 62 [29-167] | 126 [107-179] | .029 |
| Concomitant treatment, n (%) | 19 (54.3) | 7 (20.0) | .003 |
| Adverse events under eltrombopag, n (%) | 2 (5.7) | 4 (11.4) | .393 |
| Any treatment(s) after eltrombopag discontinuation, n (%) | 33 (94.3) | 4 (11.4) | <.001 |
| No. of treatments after eltrombopag discontinuation, median [Q1-Q3] | 1 [1-3] | 0 [0-0] | <.001 |
| Variable . | Refractory to eltrombopag (n = 35) . | Responders to eltrombopag (n = 35) . | Statistical significance (P) . |
|---|---|---|---|
| No. of DNA variants present in the patient, median [Q1-Q3] | 4 [3-5] | 2 [1-2] | <.001 |
| Age at diagnosis, y, median [Q1-Q3] | 48 [38-69] | 55 [43-67] | .447 |
| Age at diagnosis ≥ 65 y, n (%) | 11 (31.4) | 10 (28.6) | .794 |
| Male/female, n | 18/17 | 11/24 | .089 |
| CCI > 1, n (%) | 2 (5.7) | 5 (14.3) | .232 |
| Months with ITP, median [Q1-Q3] | 14 [8-114] | 12 [5-55] | .039 |
| Platelet count at diagnosis (×109/L), median [Q1-Q3] | 7 [4-16] | 16 [6-30] | .202 |
| Asymptomatic at diagnosis, n (%) | 19 (59.4) | 26 (74.3) | .194 |
| Bleeding at diagnosis, n (%) | 24 (75.0) | 21 (60.0) | .192 |
| Type of primary ITP, n (%) | 35 (100) | 35 (100) | |
| Newly diagnosed | 5 (14.3) | 8 (22.9) | .356 |
| Persistent | 6 (17.1) | 8 (22.9) | .550 |
| Chronic | 24 (68.6) | 19 (54.3) | .220 |
| Eltrombopag treatment duration (mo), median [Q1;Q3] | 3 [1;9] | 44 [27;75] | < .001 |
| Past ITP treatments, median [Q1-Q3] | 2 [2-4] | 1 [1-3] | .005 |
| Romiplostim, n (%) | 14 (40.0) | 4 (11.4) | .006 |
| IV immunoglobulins, n (%) | 16 (45.7) | 8 (22.9) | .044 |
| Rituximab, n (%) | 12 (34.3) | 2 (5.7) | .003 |
| Splenectomy, n (%) | 14 (40.0) | 2 (5.7) | .001 |
| Vincristine, n (%) | 1 (2.9) | 2 (5.7) | .555 |
| Three or more previous treatment lines, n (%) | 17 (48.6) | 9 (25.7) | .048 |
| Platelet count at eltrombopag treatment initiation (×109/L), median [Q1-Q3] | 8 [5-30] | 25 [10-43] | .005 |
| Bleeding at eltrombopag treatment initiation, n (%) | 19 (54.3) | 7 (20.0) | .003 |
| Platelet count at last visit under eltrombopag treatment (×109/L), median [Q1-Q3] | 15 [8-26] | 125 [105-174] | <.001 |
| Platelet count at last visit follow-up under any ITP drug (×109/L), median [Q1-Q3] | 65 [22-115] | 126 [110-182] | .003 |
| Platelet count at last visit follow-up (×109/L), median [Q1-Q3] | 62 [29-167] | 126 [107-179] | .029 |
| Concomitant treatment, n (%) | 19 (54.3) | 7 (20.0) | .003 |
| Adverse events under eltrombopag, n (%) | 2 (5.7) | 4 (11.4) | .393 |
| Any treatment(s) after eltrombopag discontinuation, n (%) | 33 (94.3) | 4 (11.4) | <.001 |
| No. of treatments after eltrombopag discontinuation, median [Q1-Q3] | 1 [1-3] | 0 [0-0] | <.001 |